Literature DB >> 8591940

Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia.

A G Prentice1, D W Warnock, S A Johnson, P C Taylor, D A Oliver.   

Abstract

The multiple dose pharmacokinetics of a solution of itraconazole given orally were measured in an open study of 20 patients undergoing remission induction chemotherapy for acute myeloid leukaemia. Patients were given itraconazole 5 mg/kg od, 2.5 mg/kg bd, 2.5 mg/kg od or 1.25 mg/kg bd. The mean daily dose of itraconazole was 407 mg for patients receiving 5 mg/kg/day and 148 mg in patients receiving 2.5 mg/kg/day. Mean concentrations of 493 and 495 micrograms/L were achieved on day 8 in patients who received 5 mg/kg/d od or 2.5 mg/kg bd itraconazole respectively. However, mean concentrations were significantly lower for those who received 2.5 mg/kg od itraconazole being 110 micrograms/L on day 8. Mean areas under the serum-concentration time curves were also markedly higher in patients receiving 5 mg/kg/day than in those receiving 2.5 mg/kg/day itraconazole and were 22,382 and 5615 micrograms.h/L on day 15 respectively. These findings suggest that the serum concentrations attained with an oral solution of 5 mg/kg itraconazole either once daily or in two divided doses are suitable for antifungal prophylaxis in patients receiving chemotherapy for acute myeloid leukaemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8591940     DOI: 10.1093/jac/36.4.657

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

1.  Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis.

Authors:  C Schmitt; Y Perel; J L Harousseau; S Lemerle; E Chwetzoff; J P le Moing; J C Levron
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.

Authors:  J A Barone; B L Moskovitz; J Guarnieri; A E Hassell; J L Colaizzi; R H Bierman; L Jessen
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

3.  Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation.

Authors:  Hyery Kim; Donghoon Shin; Hyoung Jin Kang; Kyung-Sang Yu; Ji Won Lee; Sung Jin Kim; Min Sun Kim; Eun Sun Song; Mi Kyoung Jang; June Dong Park; In-Jin Jang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  Clin Drug Investig       Date:  2015-07       Impact factor: 2.859

4.  Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.

Authors:  Gopal Krishna; Angela Sansone-Parsons; Monika Martinho; Bhavna Kantesaria; Lisa Pedicone
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

5.  Epidemiology and Prevention of Invasive Aspergillosis.

Authors:  David W. Warnock; Rana A. Hajjeh; Brent A. Lasker
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

Review 6.  Therapy for fungal infections in leukemia.

Authors:  R E Segal; G Y Minamoto
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

7.  Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.

Authors:  P C Huijgens; A M Simoons-Smit; A C van Loenen; E Prooy; H van Tinteren; G J Ossenkoppele; A R Jonkhoff
Journal:  J Clin Pathol       Date:  1999-05       Impact factor: 3.411

8.  Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.

Authors:  Andreas H Groll; Lauren Wood; Maureen Roden; Diana Mickiene; Christine C Chiou; Ellen Townley; Luqman Dad; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

Review 10.  Optimisation of itraconazole therapy using target drug concentrations.

Authors:  J M Poirier; G Cheymol
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.